Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 62, Issue 7, Pages 3323-3335Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.8b01746
Keywords
-
Categories
Funding
- National Institutes of Health [R01 CA179902]
- National Science Foundation [1800126]
- Division Of Chemistry
- Direct For Mathematical & Physical Scien [1800126] Funding Source: National Science Foundation
Ask authors/readers for more resources
A series of five boron dipyrromethene (BODIPY) bioconjugates containing an epidermal growth factor receptor (EGFR)-targeted pegylated LARLLT peptide and/or a glucose or biotin ethylene diamine group were synthesized, and the binding capability of the new conjugates to the extracellular domain of EGFR was investigated using molecular modeling, surface plasmon resonance, fluorescence microscopy, competitive binding assays, and animal studies. The BODIPY conjugates with a LARLLT peptide were found to bind specifically to EGFR, whereas those lacking the peptide bound weakly and nonspecifically. All BODIPY conjugates showed low cytotoxicity (IC50 > 94 mu M) in HT-29 cells, both in the dark and upon light activation (1.5 J/cm(2)). Studies of nude mice bearing subcutaneous human HT-29 xenografts revealed that only BODIPY conjugates bearing the LARLLT peptide showed tumor localization 24 h after intravenous administration. The results of our studies demonstrate that BODIPY bioconjugates bearing the EGFR-targeting peptide 3PEG-LARLLT show promise as near-IR fluorescent imaging agents for colon cancers overexpressing EGFR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available